Mechanisms of central and peripehral T-cell tolerance: Lessons from experimental models of multiple sclerosis

Immunological Reviews

Volumn 169, Issue , 1999, Pages 123-137

  Anderton, Stephen ^b   Burkhart, Christoph ^a   Metzler, Barbara ^c   Wraith, David ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c University Walk ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MYELIN; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THYMUS; AMINO ACID SEQUENCE; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; REVIEW; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0033141481     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01311.x     Document Type: Article

References (78)

1. 1. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-280.
2. 2. Heath VL, Moore NC, Parnell SM, Mason DW. Intrathymic expression of genes involved in organ specific autoimmune disease. J Autoimmun 1998;11:309-318.
3. 3. Hanahan D. Peripheral-antigen expressing cells in the thymic medulla: factors in self-tolerance and autoimmunity. Curr Opin Immunol 1998;10:658-662.
4. 4. Griffith TS, Yu XH, Herndon JM, Green DR, Ferguson TA. CD95-induted apoptosis of lymphocytes in an immune provileged site induces immunological tolerance. Immunity 1996;5:7-16.
5. 5. Williams GA, Mammolenti MM, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III Induction of ACAID depends upon intraocular transforming growth factor-β. Eur J Immunol 1992;22:165-173.
6. 6. Lenardo M. The molecular regulation of lymphocyte apoptosis. Semin Immunol 1997;9:1-5.
7. 7. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical megative regulatory role for CTLA-4. Immunity 1995;3:541-546.
8. 8. Waterhouse P, Bachmann MF, Penninger JM, Ohashi PS, Mak TW. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol 1997;27:1887-1892.
9. 9. Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr Opin Immunol 1998;10:649-655.
10. 10. Saoudi A, Seddon B, Fowell D, Mason D. The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med 1996;184:2393-2398.
11. + T cells. J Exp Med 1996;183:2669-2674.
12. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
13. 13. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
14. 14. Sundstedt A, Hoiden I, Rosendahl A, Kalland T, Van Rooijen N, Dohlsten M. Immunoregulatory role of IL.-10 during superantigen-induced hyporesponsiveness in vivo. J Immunol 1997;158:180-186.
15. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
16. 16. Buer J, Lanoue A, Franzke A, Garcia C, von Boehmer H, Sarukhan A. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restriced T cells anergized in vivo. J Exp Med 1998;187:177-183.
17. 17. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986;324:258-260.
18. 18. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989;59:247-255.
19. 19. Wraith DC, Bruun B, Fairchild PJ. Cross-reactive antigen recognition by an encephalitogenic T cell receptor. J Immunol 1992;149:3765-3770.
20. 20. Gautam AM, Pearson CJ, Smilek DE, Steinman L, McDevitt HO. A polyalanine petide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J Exp Med 1992;176:605-609.
21. k form and dissociate rapidly at neutral pH. J Immunol 1995;154:5216-5227.
22. 22. Fugger L, Liang J, Gautam A, Rothbard JB, McDevitt HO. Quantitative analysis of peptides from myelin basic protein binding to the MHC. class II protein, I-A(u), which confers susceptibility to experimental allergic encephalomyelitis. Mol Med 1996;2:181-188.
23. 23. Anderton SM, Manickasingham SP, Burkhart C, Luckcuck T, Lamont AG, Wraith DC. Fine-specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J Immunol 1998;161:3357-3364.
24. 24. Lee C, et al. Evidence that the autoimmune antigen myelin basic protein (MBP) Ac1-9 binds towards one end of the major histocompatibility complex (MHC) cleft. J Exp Med 1998;187:1505-1516.
25. 25. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995;3:407-415.
26. 26. Zamvil S, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985;317:355-358.
27. 27. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993;72:551-560.
28. 28. Schluesener HJ, Wekerle H. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. J Immunol 1985;135:3128-3133.
29. 29. Cibotti R, et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 1992;89:416-420.
30. 30. Mamula MJ. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J Exp Med 1993;177:567-571.
31. 31. Drakesmith H, et al. In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc Natl Acad Sci USA 1998;95:14903-14908.
32. 32. Sprent J, Lo D, Gao EK, Ron Y. T cell selection in the thymus. Immunol Rev 1988;101:173-190.
33. 33. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
34. 34. Alam SM, et al. T-cell receptor affinity and thymocyte positive selection. Nature 1996;381:616-620.
35. 35. Joosten I, et al. Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int Immunol 1994;6:751-759.
36. 36. Harrington CJ, et al. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998;8:571-580.
37. 37. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998;187:2055-2063.
38. 38. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994;78:399-408.
39. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med 1998;188:1883-1894.
40. + T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J Exp Med 1998;188:1875-1882.
41. 41. Brocke S, et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 1993;365:642-644.
42. 42. Metzler B, Burkhart C, Wraith DC. Phenotypic analysis of CTLA-4 and CD-28 expression during transient peptide-induced T cell activation in vivo. Int Immunol 1999;11: 667-675.
43. 43. Lehman PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-157.
44. 44. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
45. 45. Chen Y, Inobe JI, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180.
46. 46. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991;147:2155-2163.
47. 47. Friedman A, et al. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994;91:6688-6692.
48. 48. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993;5:1159-1165.
49. 49. Metzler B, Wraith DC. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1996;778:228-243.
50. 50. Liu GY, Wraith DC. Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice - implications for autoimmunity. Int Immunol 1995;7:1255-1263.
51. 51. Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol 1998;28:1251-1261.
52. 52. Metzler B, Wraith DC, Inhibition of T cell responsiveness by nasal peptide administration: influence of the thymus and differential recovery of T cell-dependent functions. Immunology (In press).
53. 53. Anderton SM, Burkhart C, Liu GY, Metzler B, Wraith DC. Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Novartis Found Symp 1998;215:120-136.
54. + T-cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.
55. 55. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996;93:956-960.
56. 56. Tian J, et al. Nasal administration of glutamate decarboxylase (GAD 65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183:1561-1567.
57. 57. Genain CP, et al. Late complications of immune deviation therapy in nonhuman primate. Science 1996;274:2054-2057.
58. 58. Lafaille JJ, et al. Myelin basic protein-specific T helper 2 cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186:307-312 .
59. 59. Burkhart C, Liu GY, Metzler B, Wraith DC. Modulation of cytokine production following intranasal administration of antigenic peptide. Transplant Proc 1998;30:4186-4187.
60. 60. De Waal Malefyt R, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-924.
61. 61. De Waal Maelfyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
62. 62. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992;148:1143-1148.
63. + T cells. J Exp Med 1996;184:19-29.
64. 64. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997;186:159-164.
65. 65. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
66. 66. Bretscher P. The two signal model of lymphocyte activation twenty-one years later. Immunol Today 1992;13:74-76.
67. 67. Bluestone JA. Is CTLA-4 a master switch for peripheral tolerance? J Immunol 1997;158:1989-1993.
68. + T cells. J Exp Med 1998;188:1849-1857.
69. 69. Sette A, et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994;12:413-431.
70. 70. Acha-Orbea H, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988;54:263-273.
71. 71. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a sinlge T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 1996;184:1259-1268.
72. 72. Brabb T, et al. Thymic stromal organisation is regulated by the specificity of T cell receptor/major histocompatibility complex interactions. Eur J Immunol 1997;27:136-146.
73. 73. Anderton SM, Kissler S, Lamont AG, Wraith DC. Therapeutic potential of T cell receptor antagonists is determined by thier ability to modulate a diverse repertoire of autoreactive T cells. Eur J Immunol 1999;29:1850-1857.
74. 74. Gaur A, Wiers B, Liu A, Rothbard J. Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992;258:1491-1494.
75. 75. Franco A, Southwood S. Arrhenius T, Kuchroo VK, Grey HM, Sette A. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 1994;24:940-946.
76. 76. Kuchroo VK, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T-cell repertoire. J Immunol 1994;153:3326-3336.
77. 77. Nicholson LB, Murtaza A, Hafler BP, Sette A, Kuchroo VK. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc Natl Acad Sci USA 1997;94:9279-9284.
78. 78. Nicholson LB, Waldner H, Carrizosa AM, Sette A, Collins M, Kuchroo VK. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci USA 1998;95:264-269.